A pre-clinical biotech startup that was awarded more than $1 million in state money last year said it has demonstrated that a certain type of abundant stem cells significantly reduce the severity of multiple sclerosis in mice.

Farmington's ImStem Biotechnology Inc., which is a member of UConn's technology incubator, said it worked with UConn Health Center scientists and Massachusetts company Advanced Cell Technology Inc. to determine that mesenchymal stem cells (MSCs) derived from human embryonic stem cells are more effective at treating MS in mice than MSCs from the bone marrow of adult donors.

In fact, the researchers said they found unexpectedly that the use of adult bone marrow stem cells to treat MS is highly variable and may carry a previously unrecognized risk of poor outcome.

The work is published in the June 5 online edition of Stem Cell Reports.

ImStem is seeking approvals and investment for Phase 1 clinical trials.

Read the original:
Farmington startup treats MS in mice with stem cells